Toxicology and Applied Pharmacology 314 (2017) 91–97

Contents lists available at ScienceDirect

Toxicology and Applied Pharmacology

journal homepage: www.elsevier.com/locate/taap

The unexpected teratogenicity of RXR antagonist UVI3003 *via* activation of PPARγ in *Xenopus tropicalis*

Jingmin Zhu [a], Amanda Janesick [b], Lijiao Wu [a], Lingling Hu [a], Weiyi Tang [b], Bruce Blumberg [b], Huahong Shi [a,*]

[a] State Key Laboratory of Estuarine and Coastal Research, East China Normal University, Shanghai 200062, China
[b] Department of Developmental and Cell Biology, University of California, Irvine, California 92697-2300, USA

ARTICLE INFO

Article history:
Received 29 July 2016
Revised 31 October 2016
Accepted 23 November 2016
Available online 25 November 2016

Keywords:
UVI3003
TPT
Peroxisome proliferator activated receptor γ
Retinoid X receptor
Teratogenicity
Xenopus

ABSTRACT

The RXR agonist (triphenyltin, TPT) and the RXR antagonist (UVI3003) both show teratogenicity and, unexpectedly, induce similar malformations in *Xenopus tropicalis* embryos. In the present study, we exposed *X. tropicalis* embryos to UVI3003 in seven specific developmental windows and identified changes in gene expression. We further measured the ability of UVI3003 to activate *Xenopus* RXRα (xRXRα) and PPARγ (xPPARγ) *in vitro* and *in vivo*. We found that UVI3003 activated xPPARγ either in Cos7 cells (*in vitro*) or *Xenopus* embryos (*in vivo*). UVI3003 did not significantly activate human or mouse PPARγ *in vitro*; therefore, the activation of *Xenopus* PPARγ by UVI3003 is novel. The ability of UVI3003 to activate xPPARγ explains why UVI3003 and TPT yield similar phenotypes in *Xenopus* embryos. Our results indicate that activating PPARγ leads to teratogenic effects in *Xenopus* embryos. More generally, we infer that chemicals known to specifically modulate mammalian nuclear hormone receptors cannot be assumed to have the same activity in non-mammalian species, such as *Xenopus*. Rather they must be tested for activity and specificity on receptors of the species in question to avoid making inappropriate conclusions.

1. Introduction

Retinoic acid functions through two classes of receptors: the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs) (Mangelsdorf et al., 1994). These receptors are members of the nuclear receptor superfamily, modulate ligand-dependent gene expression by interacting as RXR/RAR heterodimers or RXR homodimers on specific target-gene DNA sequences known as hormone response elements (Willhite et al., 1996). In addition to their role in retinoid signaling, RXRs also serve as heterodimeric partners of nuclear receptors for vitamin D (VDR), thyroid hormone (TRs), and peroxisome proliferator activated receptors (PPARs), among others (Mangelsdorf et al., 1994). The RXRα–PPARγ heterodimer regulates transcription of genes involved in glucose and lipid homeostasis, and is considered to be a master regulator of adipocyte differentiation and lipid storage (Rosen and Spiegelman, 2001; Tontonoz and Spiegelman, 2008). Activation of PPARγ by organotins, thiazolidinediones, or lipids promotes the expression of genes that increase fatty acid storage and inhibits expression of genes that induce lipolysis (Ferré, 2004; Grün et al., 2006b; Tontonoz and Spiegelman, 2008).

In addition to natural, endogenous ligands, a few xenobiotic chemicals are known to activate or antagonize RXRs (Alsop et al., 2003; Li et al., 2008; Inoue et al., 2011; Jiang et al., 2012). It is known that RXR activation plays an important role in inducing the development of imposex in gastropods (Nishikawa et al., 2004), and RXR ligands can potentiate some of the teratogenic effects of RAR agonists in mice (*e.g.* spina bifida aperta, micrognathia, anal atresia, and tail defects) (Elmazar et al., 1997; Collins and Mao, 1999). The teratogenicity of RXR antagonists has received much less attention. However, water extracts from six major river systems and three drinking water treatment plants in China have been shown to contain RXR antagonists whereas RXR agonistic activity was not observed (Jiang et al., 2012). The RXR antagonistic activities of source water sample extracts ranged from 15.2% to 57.8% 5 μM 9-*cis*-RA (Jiang et al., 2012). Hexachlorocyclohexane (HCH), *p,p′*-dichlorodiphenyltrichloroethane (*p,p′*-DDT) and 2,4-Dichlorophenol (2,4-DCP) exhibited potent antagonistic activities at very low concentration (1×10^{-6} mol/L, ~10 times environmental level) (Li et al., 2008; Turusov et al., 2002; Li et al., 2014). RAR agonistic activity was found in seven sewage treatment plants and their receiving rivers in Beijing (Zhen et al., 2009). Taken together, these results demonstrate that an understanding of RXR antagonism and its role in teratogenicity in aquatic organisms is important.

In contrast to the fairly large collection of RXR agonists known to date (Lehmann et al., 1992; Vuligonda et al., 1996; Dawson, 2004), only a few RXR antagonists have been identified (Hashimoto and Miyachi, 2005). UVI3003 was reported to be a highly selective antagonist of RXRs and has been suggested to be a valid tool to study the function of RXRs (Nahoum et al., 2007). In our previous study, we found that UVI3003 induced multiple malformations in *X. tropicalis* embryos (Zhu et al., 2014). Unexpectedly, the phenotypes induced by UVI3003 are

* Corresponding author.
E-mail address: hhshi@des.ecnu.edu.cn (H. Shi).

http://dx.doi.org/10.1016/j.taap.2016.11.014
0041-008X/

very similar to those induced by the organotin, triphenyltin (Supplementary Fig. 1) (Zhu et al., 2014), which is a well-known RXR and PPARγ agonist (Kanayama et al., 2005 and Grün and Blumberg, 2006a). Triphenyltin has been widely used as a biocide in antifouling paints and agriculture since the 1960s (Alzieu, 1996). Therefore, we hypothesized that UVI3003 was exerting its teratogenic effects through a mechanism similar to TPT (*e.g.*, through RXR-PPARγ), but perhaps not through RXR to induce malformations in *X. tropicalis* embryos.

RXRs have varied and complex expression and functions during the development of vertebrate embryos (Kastner et al., 1994). Long-term exposure experiments make it difficult to link the exact function of RXRs and the teratogenic characteristics of chemicals. For example, the RXR antagonists UVI3003 and HX531 induced divergent malformations in *X. tropicalis* embryos following 12 h of exposure (Hu et al., 2015b). Therefore, identifying stage-specific gene expression changes in response to RXR antagonists should be useful in shedding light on teratogenic mechanisms in *X. tropicalis*.

To test our hypothesis that antagonizing RXR could produce teratogenic effects, we treated *X. tropicalis* embryos with UVI3003 and sought to distinguish phenotypic malformations and gene expression changes characteristic of seven different chemical exposure windows. We further assessed the activity of UVI3003 on xRXRα and xPPARγ by transient transfection in Cos7 cells (*in vitro*) and by microinjection of *Xenopus* embryos (*in vivo*). Our aim was to determine the molecular mechanism of teratogenicity induced by UVI3003 in *Xenopus* embryos. The data show that although UVI3003 is a *bona fide* antagonist of *Xenopus* RXR, it has the novel and unexpected ability to activate *Xenopus* PPARγ (but not mouse or human PPARγ). This can explain the similar phenotypes induced by both UVI3003 and TPT, and suggests that these occur *via* activation of PPARγ.

2. Materials and methods

2.1. Exposure experiments using Xenopus tropicalis embryos

Xenopus tropicalis adults were obtained from Nasco (Fort Atkinson, WI, USA) and maintained according to previous methods (Yu et al., 2011). Breeding was induced by subcutaneous injection of human chorionic gonadotrophin (hCG) (Zhejiang, China) as described (Yu et al., 2011; Hu et al., 2015a). The exposure experiments were conducted following the Frog Embryo Teratogenesis Assay (FETAX) protocol (Fort and Paul, 2002) with some modifications. Briefly, approximately 12 h after the second injection of hCG, adults were removed from their tanks, and embryos were harvested without removing the jelly coats (Supplementary Fig. 2). UVI3003 (Cat# 847239-17-2, Tocris Bioscience, Bristol, UK) was dissolved in DMSO and then diluted into FETAX medium. Four replicate dishes (n = 4) were used in each control or treatment group of 20 embryos for morphological observations and real-time quantitative PCR analysis.

The EC_{50} of UVI3003 is 0.5 μM after 48 h treatment from NF10 in *X. tropicalis* embryos (Zhu et al., 2014). In this study, we chose 1, 1.5, 2 μM of UVI3003 to treat embryos in short exposure windows (6–8.5 h) from gastrulation (Nieuwkoop and Faber stage 10) to larval stage (NF43). 10 embryos were collected immediately after the exposure windows ended for real-time quantitative PCR analysis; the other 10 embryos were rinsed with FETAX medium three times and maintained at 26 ± 0.5 °C in the dark for later morphological analysis. All exposure experiments ended when the control embryos reached NF43. To minimize biological variation, embryos for each exposure window were chosen from one pair of frogs.

2.2. Real-time quantitative PCR analysis of gene expression in Xenopus tropicalis embryos

Total RNA was isolated from treated *X. tropicalis* embryos preserved in RNA*later* using RNeasy® Mini Kit (QIAGEN, GmBH, Germany). RNA concentrations were measured with a SMA4000 UV–vis Spectrophotometer (Merinton, Beijing, China). Reverse transcription of 1 μg of total RNA samples was carried out using PrimeScript™ RT reagent Kit with genomic DNA Eraser (Takara, Dalian, China). Primers were designed using Primer 3 and NCBI Primer-BLAST (Supplementary Table 1). Real-time quantitative PCR was performed according to our previous method (Yu et al., 2011). For each target mRNA, melting curves and gel electrophoresis verified the specificity of the amplified products and absence of primer dimers.

2.3. Luciferase reporter assay using in vitro model (Cos 7 cells)

pCMX-GAL4 plasmid fusion constructs of nuclear receptor ligand binding domains GAL4-human RXRα (Perlmann et al., 1996), - *Xenopus laevis* RXRα (Blumberg et al., 1992), - human PPARγ (Greene et al., 1994), - mouse PPARγ (Kliewer et al., 1994) were previously described (Chamorro-García et al., 2012). We isolated *Xenopus laevis* PPARγ from a cDNA library by PCR and cloned it into pCMX-GAL4 expression vector, its cloning primers are listed in Supplementary Table 2. One microgram pCMX-GAL4 effector plasmid was co-transfected with 5 μg pCMX-β-galactosidase transfection control, 5 μg tk-$(MH100)_4$-luciferase reporter and 14 μg pUC19 carrier plasmid (per 96-well plate) into Cos7 cells using calcium phosphate-mediated transient transfection (Sambrook and Russell, 2005). UVI3003 was added in 3-fold serial dilutions from 10^{-5} and 10^{-4} M for RXRα antagonism and PPARγ activation assays, respectively. TPT was serially diluted 10-fold or 3-fold from 10^{-6} M for RXRα and PPARγ activation assays. The control compounds HX531 (RXR antagonist), IRX4204 (formerly designated AGN194204 and NRX194204, RXR agonist) and ROSI (rosiglitazone, PPARγ agonist) were tested from 10^{-5} M in 10-fold serial dilutions (Kanayasu-Toyoda et al., 2005; Vuligonda et al., 1996). All transfections were performed in triplicate and reproduced in multiple experiments.

2.4. Luciferase reporter assay using in vivo model (Xenopus laevis embryos)

Xenopus laevis eggs were fertilized *in vitro* as described previously (Janesick et al., 2012), and embryos were staged according to Nieuwkoopand Faber (Nieuwkoop and Faber, 1956). Embryos were microinjected at the 2- or 4-cell stage with 50 pg/embryo pCMX-GAL4-xPPARγ mRNA or β-galactosidase (control) mRNA together with 50 pg/embryo tk-$(MH100)_4$-luciferase reporter DNA. Microinjected embryos were treated at stage 8 with the following chemicals (in 0.1× MBS): UVI3003 (1, 5, 10 μM), TPT (0.01, 0.05, 0.1 μM), TBT (RXR and PPARγ agonist, 0.05 μM) or vehicle (0.1% DMSO). For each treatment, 25 embryos were treated in glass 60-mm Petri dishes containing 10 mL of MBS + chemical, and two replicate dishes were used for each concentration. Treated embryos were separated into five-embryo aliquots at neural stage for luciferase assays (Janesick et al., 2012, 2014). Each group of five embryos was considered one biological replicate. All animal experiments were approved and performed in accordance with Institutional Animal Care and Use Committee protocols.

2.5. Statistical analysis

Data were analyzed using SPSS16.0 software. All data were tested for homogeneity of variance with Levene's statistic, if the homogeneity value is >0.05, the variances are equal and the homogeneity of variance assumption has been met. Mean differences among control and treatments were assessed by one-way analysis of variance (ANOVA) followed by Dunnett post-hoc test. Independent samples *t*-test was used for two group comparison. The luciferase data were reported as fold change over vehicle control (0.1% DMSO) ± SEM using standard propagation of error (Bevington and Robinson, 2003). EC_{50} (half effective concentration) and IC_{50} (half inhibitory concentration) of nuclear receptor activation or antagonism assays were calculated by nonlinear regression

(variable slope) of log (concentration of agonist or antagonist) *versus* response using GraphPad Prism 5.

3. Results

3.1. Multiple malformations are induced by UVI3003 in Xenopus tropicalis embryos

Exposure to UVI3003 during different developmental windows induced obviously developmental delay and multiple malformations (Fig. 1). The most common phenotypes were reduced forehead, turbid eye lens and narrow fin in UVI3003 treatment groups. Proctodaeum elongation was observed in all NF10–19 treatment groups and in the NF19–25 high dose group, while enlarged proctodaeum phenotype occurred in late exposure windows. The teratogenic ability of UVI3003 was weak in NF 10–25 stages, while it was significantly increased in NF 25–39 and then decreased in NF 39–43. The body length of embryos decreased significantly in all NF 31–36 NF36–39 treatment groups and in the NF39–41 middle and high dose groups (Supplementary Fig. 3).

3.2. PPARγ was down-regulated by UVI3003 in Xenopus tropicalis embryos

The expression of mRNAs encoding RXRs and their heterodimeric partners RARs, PPARs and TRs were evaluated after 7 different



Fig. 1. Multiple malformations induced by UVI3003 in *X. tropicalis* embryos during different stages. Embryos were collected for morphological observations when the control embryos were cultured to stage 43. Each dish of 10 embryos was considered to be one replicate, and there were 4 dishes per group (n = 4). The percent of embryos observed with the malformation is provided in the top right of each photo. Abbreviations: af, absence of fin; bn, bent notochord; cg, cement gland; dcg, displaced cement gland; eh, edema in heart; ep, enlarged proctodaeum; f, fin; h, head; hp., hypopigmentation; n, notochord; nf, narrow fin; p, proctodaeum; pe, proctodaeum elongation; rf, reduced forehead; sp, skin pigmentation; tel, turbid eye lens; Scale bar = 0.5 mm.

UVI3003-exposure windows. We found RARβ was down-regulated in early exposure periods (Fig. 2B2), whereas RXRs, TRα and TRβ were affected after late embryogenesis treatment (Fig. 2A, D). The expression of PPARγ was clearly decreased during all the treatment periods (Fig. 2C3). We tested the effects of TPT treatment during the most sensitive exposure window and found that PPARγ was also down-regulated at high dose (Fig. 3). Thus, our results showed that PPARγ was down-regulated by UVI3003 and TPT in *X. tropicalis* embryos.

3.3. Inhibition of xRXRα and hRXRα by UVI3003

In order to better understand the phenotypes elicited by UVI3003 in *Xenopus* embryos, we sought to test the specificity of UVI3003 on *Xenopus* nuclear receptors. Transient transfection assays in Cos7 cells showed that UVI3003 inhibited the activity of *Xenopus* and human RXRα (Fig. 4A, B), yielding a half inhibitory concentration (IC_{50}) of approximately 0.2 μM (Table 1). UVI3003 was approximately 10- and 5-fold more potent on *Xenopus* and human RXRα than was another RXR antagonist HX531 (Table 1). TPT strongly activated *Xenopus* and human RXRα, and the half effective concentration (EC_{50}) was 1.3×10^{-4} μM and 2.2×10^{-4} μM (Fig. 4C, D). TPT produced noticeable cytotoxicity at 0.1 μM judged by approximately 10-fold reduced β-galactosidase activity.

3.4. Activation of xPPARγ by UVI3003

In transient transfection assays, UVI3003 fully activated xPPARγ (EC_{50} = 12.6 μM) (Table 1). The maximal activation reached the same level as a well-known agonist of PPARγ, rosiglitazone (ROSI), although



Fig. 3. mRNA expression level of *PPARγ* in *X. tropicalis* embryos exposed to triphenyltin (TPT). Embryos were exposed to 0.1% DMSO, 0.008, 0.04 and 0.08 μM TPT from NF 32 till control group embryos reached NF 40 (about 12 h in 26 ± 0.5 °C). NF 32–40 was the sensitive working window of TPT in *X. tropicalis* embryos (Yuan et al., 2011). Statistical analysis was conducted with one-way ANOVA followed by Dunnett test. $^{*}p < 0.05$.

UVI3003 was not as efficacious as ROSI (Fig. 5A). In contrast, UVI3003 was almost completely inactive on hPPARγ and mPPARγ (Fig. 5B–C).

Next, we tested the ability of UVI3003 to activate xPPARγ, *in vivo*. xPPARγ mRNA and luciferase reporter DNA were microinjected into *Xenopus* embryos. The results showed that UVI3003 could activate xPPARγ (Fig. 6). 1 μM UVI3003 significantly activated xPPARγ (~2-fold), similar to the activation observed with either 0.05 μM TPT or



Fig. 2. mRNA expression levels of *RXRs, RARs, PPARs* and *TRs* in *X. tropicalis* embryos exposed to UVI3003 during different windows. The x-axis shows seven exposure windows NF10–19, NF19–25, NF25–31, NF31–36, NF36–39, NF39–41 and NF41–43. The embryos were collected immediately after the exposure windows ended for real-time quantitative PCR analysis. Each dish of 10 embryos was considered one replicate, and there were 4 replicate dishes per group (n = 4). The y-axis shows the fold change compared to 0.1% DMSO control groups (positive: up-regulated; minus: down-regulated). Each value represents the mean ± SEM of four replicates. Statistical analysis was conducted with one-way ANOVA followed by Dunnett test. $^{*}p < 0.05$, $^{**}p < 0.01$ and $^{***}p < 0.001$.



Fig. 4. Antagonism of xRXRα and hRXRα by UVI3003 *in vitro* by transient transfection assays. HX531 and AGN194204 are the control antagonist and agonist of RXRα. A–B, UVI3003 antagonizes GAL4-xRXRα, GAL4-hRXRα against 10 nM 4204. C–D, TPT activates GAL4-xRXRα, GAL4-hRXRα with EC_{50} 1.3×10^{-4} μM and 2.2×10^{-4} μM. Data represent reporter luciferase activity normalized to β-galactosidase and plotted as the average fold change ± SEM (n = 3) relative to DMSO (0.05%) controls.



Fig. 5. Activation of xPPARγ by UVI3003 (*in vitro*). Rosiglitazone (ROSI) and AGN194204 are the control agonists of PPARγ and RXRα. Data represent reporter luciferase activity normalized to β-galactosidase and plotted as the average fold change ± SEM (n = 3) relative to DMSO (0.05%) controls.

0.05 μM TBT (Fig. 6). Increasing the dose to 5 μM or 10 μM, UVI3003 enhanced activation of xPPARγ to 3–3.5 fold over DMSO controls. TPT activated xPPARγ in an appropriate, concentration-dependent manner.

4. Discussion

In the present paper, we employed a modified frog embryo teratogenesis assay *Xenopus* (FETAX) protocol (Fort and Paul, 2002; Yu et al., 2011) to assess UVI3003-induced malformations in *X. tropicalis* embryos specific to certain developmental windows of chemical exposure. In a previous study, we found that the well-known agonist of RXR, triphenyltin (TPT), induced stage-specific malformations and phenotypic changes in *Xenopus* embryos (Yuan et al., 2011). Both UVI3003 and TPT showed higher toxicity during late embryogenesis and shared very similar characteristics such as reduced forehead, turbid eye lens, enlarged proctodaeum and narrow fin (Supplementary Fig. 1) (Yuan et al., 2011; Yu et al., 2011; Zhu et al., 2014). These malformations and developmental delay occurred in both *Xenopus tropicalis* and *laevis* embryos (Supplementary Fig. 1).

The gene expression data showed that 1–2 μM UVI3003 and 0.08 μM TPT down-regulated PPARγ in *X. tropicalis* embryos. PPARγ mRNA expression is most abundant in adipose tissue in vertebrate (Michalik et al., 2002) and has been known as a dominant and essential regulator of both brown and white adipocyte differentiation *in vitro* and *in vivo* (Barak et al., 1999; Kubota et al., 1999; Rosen et al., 1999). Grün et al. (2006b) found that in mouse liver and testis organs, *PPARγ* expression was decreased after treatment with TBT (tributyltin) and troglitazone (PPARγ agonist). The exposure of zebrafish to 10 ng Sn/L TBT from pre-hatching to 9 months of age alters the bodyweight, hepatosomatic index and up-regulated the transcription of PPARγ in liver (Lyssimachou et al., 2015). Thus, the expression of PPARγ was regulated by PPARγ activating ligands but its change is different among species and organs.

Our reporter assays showed that although UVI3003 is a *bona fide* antagonist of RXRs in *Xenopus*, it has an unexpected ability to activate *Xenopus* PPARγ but not mouse or human PPARγ. Therefore, chemicals that are stated to activate or antagonize mammalian nuclear hormone receptors cannot be assumed to possess the same activity, or the same selectivity for receptors of non-mammalian species, such as *Xenopus*. The differences in the activation of PPARγ by UVI3003 in different species might be due to the different sequence of PPARγ in specific species. For example, certain phthalates, perfluorinated compounds and halogenated derivatives of BPA are common activators of human PPARγ and

Table 1
Ligand IC_{50} and EC_{50} values for nuclear receptor LBDs.

Gal4-NR LBD	IC_{50} values, μM		EC_{50} values, μM	
	UVI3003	HX531	TPT	4204
xRXRα	0.22	2.8	1.3×10^{-4}	1.7×10^{-3}
hRXRα	0.24	1.0	2.2×10^{-4}	1.2×10^{-3}
	EC_{50} values, μM			
	UVI3003	TPT	ROSI	4204
xPPARγ	12.6	0.01	0.74	Na
hPPARγ	ND	0.02	0.51	Na
mPPARγ	ND	0.07	0.14	Na

na, not active; ND, not determined. IC_{50} and EC_{50} values were calculated from nonlinear regression analysis of dose-response curves of GAL4-NR LBD activation or inhibition in transiently transfected Cos7 cells after 24 h ligand exposure.



Fig. 6. Activation of xPPARγ by UVI3003 and TPT in *X. laevis* embryos. Embryos were injected at the 2- or 4-cell stage with 50 pg reporter DNA, and 50 pg Gal4-xPPARγ mRNA then treated at stage 8 with TPT, UVI3003, TBT (0.05 μM) or vehicle (0.1% DMSO). Each value represents the mean ± SEM of three or four replicates (n = 3, 4). Statistical analysis was conducted with one-way ANOVA (Dunnett test) and independent samples *t*-test. $^{*}p < 0.05$, $^{**}p < 0.01$ and $^{***}p < 0.001$.

zebrafish PPARγ, whereas the potent pharmaceutical hPPARγ agonists thiazolidones are not recognized by zebrafish PPARγ (Grimaldi et al., 2015; Riu et al., 2014). Comparison of human and zebrafish PPARγ sequences reveals that several residue differences could explain the differential ligand specificity of the various species (Grimaldi et al., 2015). Thus, conclusions based on assumptions about the specificity of mammalian receptor-selective ligands toward non-mammalian species may not be accurate. Our work highlights the need to test the activity of such chemicals against receptors of the target species before making inferences about the mechanisms through which they act.

In brief, we documented for the first time that a well-known RXRs antagonist (UVI3003) could also activate xPPARγ, but this unique characteristic only occurred in *Xenopus* rather than in mouse or human *in vitro*. Further *in vivo* work is needed to clarify the difference among species using UVI3003. Our results indicate that PPARγ is likely to play a critical role in inducing malformations in *Xenopus* embryos after exposure to UVI3003.

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.taap.2016.11.014.

Conflict of interest statement

None of the authors have competing interests. Every author has seen and contributed to the final draft, and also agree the manuscript is ready to submit.

Transparency document

The Transparency document associated with this article can be found, in the online version.

Acknowledgements

This work was supported by grants from the Natural Science Foundation of China (21277049) and by a grant from NIH (1R01ES023316) to B.B. We thank Yixuan Pan for comments and Qiang Zhang for help with the RT-qPCR analysis.

References

Alsop, D., Hewitt, M., Kohli, M., Brown, S., Van Der Kraak, G., 2003. Constituents within pulp mill effluent deplete retinoid stores in white sucker and bind to rainbow trout retinoic acid receptors and retinoid X receptors. Environ. Toxicol. Chem. 22 (12), 2969–2976.

Alzieu, C.L., 1996. Biological effects of tributyltin on marine organisms. Tributyltin: Case Study of an Environmental Contaminant. 8, pp. 167–211.

Barak, Y., Nelson, M.C., Ong, E.S., Jones, Y.Z., Ruiz-Lozano, P., Chien, K.R., Koder, A., Evans, R.M., 1999. PPARγ is required for placental, cardiac, and adipose tissue development. Mol. Cell 4 (4), 585–595.

Bevington, P.R., Robinson, D.K., 2003. Data Reduction and Error Analysis. Mc Graw-Hill.

Blumberg, B., Mangelsdorf, D.J., Dyck, J.A., Bittner, D.A., Evans, R.M., De Robertis, E.M., 1992. Multiple retinoid-responsive receptors in a single cell: families of retinoid "X" receptors and retinoic acid receptors in the *Xenopus* egg. Proc. Natl. Acad. Sci. U. S. A. 89 (6), 2321–2325.

Chamorro-García, R., Kirchner, S., Li, X., Janesick, A., Casey, S.C., Chow, C., Blumberg, B., 2012. Bisphenol A diglycidyl ether induces adipogenic differentiation of multipotent stromal stem cells through a peroxisome proliferator-activated receptor gamma-independent mechanism. Environ. Health Perspect. 120 (7), 984.

Collins, M.D., Mao, G.E., 1999. Teratology of retinoids. Annu. Rev. Pharmacol. Toxicol. 39 (1), 399–430.

Dawson, M.I., 2004. Synthetic retinoids and their nuclear receptors. Curr. Med. Chem.: Anti-Cancer Agents 4, 199–230.

Elmazar, M.M., Ruhl, R., Reichert, U., Shroot, B., Nau, H., 1997. RAR alpha mediated teratogenicity in mice is potentiated by an RXR agonist and reduced by an RAR antagonist: dissection of retinoid receptor-induced pathways. Toxicol. Appl. Pharmacol. 146, 21–28.

Ferré, P., 2004. The biology of peroxisome proliferator-activated receptors relationship with lipid metabolism and insulin sensitivity. Diabetes 53 (Suppl. 1), S43–S50.

Fort, D.J., Paul, R.R., 2002. Enhancing the predictive validity of frog embryo teratogenesis assay-*Xenopus* (FETAX). J. Appl. Toxicol. 22, 185–191.

Greene, M.E., Blumberg, B., McBride, O.W., Yi, H.F., Kronquist, K., Kwan, K., Hsieh, L., Greene, G., Nimer, S.D., 1994. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. 4 (4–5), 281–299.

Grimaldi, M., Boulahtouf, A., Delfosse, V., Thouennon, E., Bourguet, W., Balaguer, P., 2015. Reporter cell lines to evaluate the selectivity of chemicals for human and zebrafish estrogen and peroxysome proliferator activated γ receptors. Front. Neurosci. 9.

Grün, F., Blumberg, B., 2006a. Environmental obesogens: organotins and endocrine disruption via nuclear receptor signaling. Endocrinology 147, S50–S55.

Grün, F., Watanabe, H., Zamanian, Z., Maeda, L., Arima, K., Chubacha, R., Gardiner, D.M., Kanno, J., Iguchi, T., Blumberg, B., 2006b. Endocrine disrupting organotin compounds are potent inducers of adipogenesis in vertebrates. Mol. Endocrinol. 20, 2141–2155.

Hashimoto, Y., Miyachi, H., 2005. Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis. Bioorg. Med. Chem. 13, 5080–5093.

Hu, L.L., Zhu, J.M., Rotchell, J.M., Wu, L.J., Gao, J.J., Shi, H.H., 2015a. Use of the enchanced forg embryo teratogenesis assay-*Xenopus* (FETAX) to determine chemically-induced phenotypic effects. Sci. Total Environ. 508, 258–265.

Hu, L.L., Wu, L.J., Xue, Y.G., Zhu, J.M., Shi, H.H., 2015b. An assay to determine the sensitive window of embryos to chemical exposure using *Xenopus tropicalis*. J. Appl. Toxicol. 36, 685–691.

Inoue, D., Nakama, K., Sawada, K., Watanabe, T., Matsui, H., Sei, K., Nakanishi, T., Ike, M., 2011. Screening of agonistic activities against four nuclear receptors in wastewater treatment plants in Japan using a yeast two-hybrid assay. J. Environ. Sci. 23 (1), 125–132.

Janesick, A., Shiotsugu, J., Taketani, M., Blumberg, B., 2012. RIPPLY3 is a retinoic acid-inducible repressor required for setting the borders of the pre-placodal ectoderm. Development 139 (6), 1213–1224.

Janesick, A., Nguyen, T.T., Aisaki, K.I., Igarashi, K., Kitajima, S., Chandraratna, R.A.S., Kanno, J., Blumberg, B., 2014. Active repression by RARγ signaling is required for vertebrate axial elongation. Development 141 (11), 2260–2270.

Jiang, W.W., Yan, Y., Li, N., Ma, M., Wang, D.H., Rao, K.F., Wang, Z.J., Satyanarayanan, S.K., 2012. Retinoid X receptor activities of source waters in China and their removal efficiencies during drinking water treatment processes. Chin. Sci. Bull. 57 (6), 595–600.

Kanayama, T., Kobayashi, N., Mamiya, S., Nakanishi, T., Nishikawa, J.I., 2005. Organotin compounds promote adipocyte differentiation as agonists of the peroxisome proliferator-activated receptor γ/retinoid X receptor pathway. Mol. Pharmacol. 67 (3), 766–774.

Kanayasu-Toyoda, T., Fujino, T., Oshizawa, T., Suzuki, T., Nishimaki-Mogami, T., Sato, Y., Sawada, J.-i., Inoue, K., Shudo, K., Ohno, Y., Yamaguchi, T., 2005. HX531, a retinoid X receptor antagonist, inhibited the 9-cis retinoic acid-induced binding with steroid receptor coactivator-1 as detected by surface plasmon resonance. J. Steroid Biochem. 94 (4), 303–309.

Kastner, P., Grondona, J.M., Mark, M., Gansmuller, A., LeMeur, M., Decimo, D., Vonesch, J.L., Dollé, P., Chambon, P., 1994. Genetic analysis of RXRα developmental function: convergence of RXR and RAR signaling pathways in heart and eye morphogenesis. Cell 78 (6), 987–1003.

Kliewer, S.A., Forman, B.M., Blumberg, B., Ong, E.S., Borgmeyer, U., Mangelsdorf, D.J., Umesono, K., Evans, R.M., 1994. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U. S. A. 91 (15), 7355–7359.

Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., et al., 1999. PPARγ mediates high-fat diet–induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4 (4), 597–609.

Lehmann, J.M., Jong, L., Fanjul, A., Cameron, J.F., Lu, X.P., Haefner, P., Dawson, M.I., Pfahl, M., 1992. Retinoids selective for retinoid X receptor response pathways. Science (Washington, DC, U. S.) 258, 1944–1946.

Li, J., Ma, M., Wang, Z.J., 2008. A two-hybrid yeast assay to quantify the effects of xenobiotics on retinoid X receptor-mediated gene expression. Toxicol. Lett. 176 (3), 198–206.

Li, C.C., Cheng, Y.B., Tang, Q., Lin, S.B., Li, Y.H., Hu, X.J., Nian, J., Gu, H., Lu, Y.F., Tang, H., Dai, S.G., Zhang, H.Q., Jin, C., Zhang, H.J., Jin, Y.Y., Jin, Y.L., 2014. The association between prenatal exposure to organochlorine pesticides and thyroid hormone levels in newborns in Yancheng, China. Environ. Res. 129, 47–51.

Lyssimachou, A., Santos, J.G., André, A., Soares, J., Lima, D., Guimarães, L., Almeida, C.M.R., Teixeira, C., Castro, L.F.C., Santos, M.M., 2015. The mammalian "obesogen" tributyltin targets hepatic triglyceride accumulation and the transcriptional regulation of lipid metabolism in the liver and brain of zebrafish. PLoS One 10 (12), e0143911.

Mangelsdorf, D.J., Umesono, K., Evans, R.M., 1994. The Retinoid Receptors.

Michalik, L., Desvergne, B., Dreyer, C., Gavillet, M., Laurini, R.N., Wahli, W., 2002. PPAR expression and function during vertebrate development. Int. J. Dev. Biol. 46 (1), 105–114.

Nahoum, V., Pérez, E., Germain, P., Rodríguez-Barrios, F., Manzo, F., Kammerer, S., Lemaire, G., Hirsch, O., Royer, C.A., Gronemeyer, H., de Lera, A.R., Bourguet, W., 2007. Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function. Proc. Natl. Acad. Sci. U. S. A. 104 (44), 17323–17328.

Nieuwkoop, P.D., Faber, J., 1956. Normal Table of *Xenopus laevis (Daudin)*. A Systematical and Chronological Survey of the Development from the Fertilized Egg Till the End of Metamorphosis.

Nishikawa, J.I., Mamiya, S., Kanayama, T., Nishikawa, T., Shiraishi, F., Horiguchi, T., 2004. Involvement of the retinoid X receptor in the development of imposex caused by organotins in gastropods. Environ. Sci. Technol. 38 (23), 6271–6276.

Perlmann, T., Umesono, K., Rangarajan, P.N., Forman, B.M., Evans, R.M., 1996. Two distinct dimerization interfaces differentially modulate target gene specificity of nuclear hormone receptors. Mol. Endocrinol. 10, 958–966.

Riu, A., McCollum, C.W., Pinto, C.L., Grimaldi, M., Hillenweck, A., Perdu, E., Zalko, D., Bernard, L., Laudet, V., Balaguer, P., Bondesson, M., Gustafsson, J.A., 2014. Halogenated bisphenol-A analogs act as obesogens in zebrafish larvae (*Danio rerio*). Toxicol. Sci. 139 (1), 48–58.

Rosen, E.D., Spiegelman, B.M., 2001. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276 (41), 37731–37734.
Rosen, E.D., Sarraf, P., Troy, A.E., Bradwin, G., Moore, K., Milstone, D.S., Spiegelman, B.M., Mortensen, R.M., 1999. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4 (4), 611–617.
Sambrook, J., Russell, D.W., 2005. Calcium-phosphate-mediated transfection of eukaryotic cells with plasmid DNAs. CSH Protoc. (1), 2368–2375.
Tontonoz, P., Spiegelman, B.M., 2008. Fat and beyond: the diverse biology of PPARγ. Annu. Rev. Biochem. 77, 289–312.
Turusov, V., Rakitsky, V., Tomatis, L., 2002. Dichlorodiphenyltrichloroethane (DDT): ubiquity, persistence, and risks. Environ. Health Perspect. 110 (2), 125.
Vuligonda, V., Lin, Y., Chandraratna, R.A.S., 1996. Synthesis of highly potent RXR-specific retinoids: the use of a cyclopropyl group as a double bond isostere. Bioorg. Med. Chem. Lett. 6 (2), 213–218.
Willhite, C.C., Dawson, M.I., Reichert, U., 1996. Receptor-selective retinoid agonists and teratogenic activity. Drug Metab. Rev. 28 (1–2), 105–119.
Yu, L., Zhang, X.L., Yuan, J., Cao, Q.J., Liu, J.Q., Zhu, P., Shi, H.H., 2011. Teratogenic effects of triphenyltin on embryos of amphibian (*Xenopus tropicalis*): a phenotypic comparison with the retinoid X and retinoic acid receptor ligands. J. Hazard. Mater. 192, 1860–1868.
Yuan, J., Zhang, X.L., Yu, L., Sun, Z., Zhu, P., Wang, X.R., Shi, H.H., 2011. Stage-specific malformations and phenotypic changes induced in embryos of amphibian (*Xenopus tropicalis*) by triphenyltin. Ecotoxicol. Environ. Saf. 74, 1960–1966.
Zhen, H., Wu, X., Hu, J., Xiao, Y., Yang, M., Hirotsuji, J., Nishikawa, J.I., Nakanishi, T., Ike, M., 2009. Identification of retinoic acid receptor agonists in sewage treatment plants. Environ. Sci. Technol. 43 (17), 6611–6616.
Zhu, J.M., Shi, H.H., Zhu, P., Hu, L.L., Wu, L.J., Yang, Y., Rotchell, J.M., 2014. Effects of antagonist of retinoid X receptor (UVI3003) on morphology and gene profile of *Xenopus tropicalis* embryos. Environ. Toxicol. Pharmacol. 38 (1), 153–162.